Eur Urol. 2012 Jun;61(6):1107-9. doi: 10.1016/j.eururo.2012.03.037. Epub 2012 Mar 24.

Thwarting high-risk prostate cancer: the right treatments for the right patients.

High-risk prostate cancer: from definition to contemporary management. [Eur Urol. 2012]
High-risk prostate cancer: from definition to contemporary management.Bastian PJ, Boorjian SA, Bossi A, Briganti A, Heidenreich A, Freedland SJ, Montorsi F, Roach M 3rd, Schröder F, van Poppel H, et al. Eur Urol. 2012 Jun; 61(6):1096-106. Epub 2012 Feb 24.

Supplemental Content

[Treatment of prostate cancer]. [Orv Hetil. 2010]
[Treatment of prostate cancer].
Romics I. Orv Hetil. 2010 Apr 4; 151(14):580-3.
The prostate cancer conundrum. [J Natl Cancer Inst. 2003]
The prostate cancer conundrum.
Albertsen PC. J Natl Cancer Inst. 2003 Jul 2; 95(13):930-1.
[Neoadjuvant hormonal therapy for prostate cancer]. [Nihon Rinsho. 2005]
[Neoadjuvant hormonal therapy for prostate cancer].
Miyakita H. Nihon Rinsho. 2005 Feb; 63(2):309-13.
Review [LHRH agonists in prostate cancer]. [Prog Urol. 2007]
Review [LHRH agonists in prostate cancer].
Rossi D, Cornu JN, Rouprêt M. Prog Urol. 2007 Apr; 17(2 Suppl 1):287-90.
Review [Conference on the treatment of prostatic cancer. Munich, Germany, 2-3 November 1996]. [Prog Urol. 1997]
Review [Conference on the treatment of prostatic cancer. Munich, Germany, 2-3 November 1996].
Lansiaux P. Prog Urol. 1997 Dec; 7(6):1020-2.

Thwarting high-risk prostate cancer: the right treatments for the right patients...
Thwarting high-risk prostate cancer: the right treatments for the right patients.
Eur Urol. 2012 Jun ;61(6):1107-9. doi: 10.1016/j.eururo.2012.03.037. Epub 2012 Mar 24 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.